Raymond James Financial
NVNO

Raymond James Financial’s enVVeno Medical NVNO Stock Holding History

Raymond James Financial’s Portfolio NVNO Stock Details NVNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-58
Closed -$8.05K – 6147
2025
Q2 		$8.05K Buy
+58
New +$6.86K ﹤0.01% 6012

Other funds holding NVNO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Raymond James Financial's NVNO Position: Q3 2025 in Review

Raymond James Financial sold out of enVVeno Medical (NVNO) in Q3 2025, closing a stake of 58 shares — an estimated $8.05K sold.

Raymond James Financial first reported a position in NVNO in Q2 2025 and held it in 1 quarter. The position peaked at $8.05K in Q2 2025. 36 funds tracked by Wall St. Rank hold NVNO as of Q3 2025.

  • Raymond James Financial reported no remaining enVVeno Medical position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 58 enVVeno Medical shares in Q3 2025, an estimated $8.05K.
  • Raymond James Financial first reported a position in enVVeno Medical in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's enVVeno Medical position peaked at $8.05K in Q2 2025.
  • 36 funds tracked by Wall St. Rank held enVVeno Medical as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.